Results 131 to 140 of about 22,979 (272)

Safety, Tolerability, and Pharmacokinetics of GMDTC for Cadmium Poisoning: A Randomized Phase 1a/1b Trial

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 160-167, July 2026.
Cadmium exposure causes serious health consequences; however, there is no clinically approved antidote for cadmium poisoning. This Phase 1a/1b trial aimed to investigate safety, tolerability, and pharmacokinetics of Sodium (S)‐2‐(dithiocarboxylato((2S,3R,4R,5R)‐2,3,4,5,6‐pentahydroxyhexyl) amino)‐4‐(methylthio) butanoate (GMDTC), a novel chelating ...
Xuefeng Ren   +21 more
wiley   +1 more source

Tokenizacióndel vino: la oportunidad de la tecnología DLT para los retos económicos y sociales del sector vinícola

open access: yes
La tokenización del vino es uno de los retos más formidables a los que se enfrenta la industria vitivinícola en el proceso de digitalización de los próximos años.
Palomo-Zurdo, Ricardo   +1 more
core   +1 more source

A Knowledge Base of Designs and Statistical Methods for Adaptive Clinical Dose‐Finding Trials

open access: yesPharmaceutical Statistics, Volume 25, Issue 4, July/August 2026.
ABSTRACT Adaptive clinical dose‐finding trials aim to identify an optimal drug dose for use in subsequent phase II and III trials. In adaptive dose‐finding trials, dose levels for newly included patients are informed by outcomes of patients that received the drug earlier in the trial.
Rob Kessels   +8 more
wiley   +1 more source

Toimitusketjun jäljitettävyys julkisella DLT-teknologialla : Hedera Hashgraph [PDF]

open access: yes
Tänä päivänä monet valtiot, organisaatiot ja yritykset tutkivat aktiivisesti, missä ja miten DLT teknologiaa voi hyödyntää olemassa olevien prosessien parantamiseen ja uusien käyttökohteiden luomiseen.
Vaccari, Daniele
core  

Drug Interactions of Vebreltinib, a Novel Type I c‐Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants

open access: yesClinical and Translational Science, Volume 19, Issue 7, July 2026.
Pharmacokinetic and drug–drug interaction evaluation of vebreltinib in healthy participants, showing decreased exposure with rifampin and increased exposure with itraconazole. ABSTRACT Vebreltinib is a novel, highly selective type I c‐Met inhibitor developed for treating non–small cell lung cancer (NSCLC) and glioma.
Jingcheng Chen   +15 more
wiley   +1 more source

Venetoclax‐Integrated Conditioning Strategies Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Myeloid Neoplasms: A Scoping Review of Emerging Evidence

open access: yesEuropean Journal of Haematology, Volume 117, Issue 1, Page 117-131, July 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remains the only potentially curative therapy for many patients with high‐risk myeloid neoplasms, yet relapse and transplant‐related toxicity continue to limit durable benefit.
Mohammed Abdulgayoom   +5 more
wiley   +1 more source

Coalition Formation for Sustainable Blockchain Governance: Insights From the Hedera Case

open access: yesInformation Systems Journal, Volume 36, Issue 4, Page 485-499, July 2026.
ABSTRACT Sustainable governance is essential for blockchain networks to achieve widespread adoption and deliver long‐term business value. Prior blockchain initiatives indicate that inadequate governance structures often lead to limited adoption or eventual project failure, underscoring the importance of decentralised governance for building resilient ...
Christophe Viguerie, Horst Treiblmaier
wiley   +1 more source

Coaxial Placement of Fogarty Catheter: A Simple Remedy for Incomplete Lung Isolation with DLT

open access: yesThe Indian Anaesthetists' Forum, 2015
Thoracic surgery requires lung isolation which is usually achieved by placing a double lumen tube (DLT). Correct placement of DLT is crucial for lung isolation. In this case report incomplete lung isolation with DLT was corrected using a Fogarty catheter
Amit Kumar Mittal   +4 more
doaj  

Vaccination and transfusion safety at the time of expanding use of live attenuated vaccines

open access: yes
Vox Sanguinis, EarlyView.
Pierre Tiberghien   +4 more
wiley   +1 more source

CPX‐351 in High‐Risk Relapsed Pediatric Acute Leukemia: Real‐World Phase 1 Data Establishing the FDA‐Approved Dose

open access: yesPediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Background/Objectives Outcomes for pediatric relapsed/refractory (R/R) acute myeloid leukemia (AML) remain dismal. CPX‐351, a liposomal formulation of cytarabine and daunorubicin, may have less off‐target toxicities than traditional chemotherapies and has shown improved outcomes for adults with newly diagnosed therapy‐related AML.
Jonathan D. Bender   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy